Vinorelbine

Vinorelbine (Navelbine) is the first 5´NOR semi-synthetic vinca alkaloid and exerts its activity through the MAPK (p38) pathway with median IC90 and IC50 of 15.5 and 2.3 μM. Vinorelbine (Navelbine) is obtained by semi-synthesis from alkaloids extracted from the rosy periwinkle, Catharanthus roseus. Vinorelbine (Navelbine) is an anti-mitotic chemotherapy agent that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. In MCF-7 and MDA-MB-468, increased p38 activity was demonstrated following vinorelbine but not doxorubicin treatment, whether vinorelbine was given prior to or simultaneously with doxorubicin. Mitogen-activated protein kinase (MAPK) activity and p53 expression remained unchanged following vinorelbine treatment.